Clene Inc. Common Stock (CLNN) Stock Price

CLNNStock

$4.44−21.64%52W

Market Cap$57.05M

P/E—

PEG Ratio—

Div yield—

Beta0.93

CLNN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-13.13%

Price vs S&P 500 (4W)-14.17%

VGM Score22.24

Book Value / Share (Quarterly)$0.66

P/TBV (Annual)18.25x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-24.78%

Cash Flow / Share (Quarterly)$-1.54

Price vs S&P 500 (YTD)-36.41%

Gross Margin (TTM)82.84%

Net Profit Margin (TTM)-25009.70%

EPS (TTM)$-3.18

10-Day Avg Trading Volume0.08M

EPS Excl Extra (TTM)$-3.18

Revenue Growth (5Y)-0.97%

EPS (Annual)$-2.65

ROI (Annual)-123.54%

Gross Margin (Annual)78.50%

Net Profit Margin (5Y Avg)-7979.03%

Cash / Share (Quarterly)$0.50

Revenue Growth QoQ (YoY)-81.48%

ROA (Last FY)-144.35%

Revenue Growth TTM (YoY)-61.71%

EBITD / Share (TTM)$-1.86

ROE (5Y Avg)-1408.09%

Operating Margin (TTM)-15722.39%

Cash Flow / Share (Annual)$-1.71

P/B Ratio12.56x

P/B Ratio (Quarterly)12.65x

Net Income / Employee (Annual)$-331,300

EV / Revenue (TTM)491.10x

Net Interest Coverage (TTM)-8.27x

ROA (TTM)-159.15%

EPS Incl Extra (Annual)$-2.65

Current Ratio (Annual)0.83x

Quick Ratio (Quarterly)1.93x

3-Month Avg Trading Volume0.37M

52-Week Price Return-21.64%

Revenue / Employee (TTM)$1,700

Tangible BV / Share (Quarterly)$0.17

P/S Ratio (Annual)267.71x

Asset Turnover (Annual)0.01x

52-Week High$13.50

Operating Margin (5Y Avg)-8926.11%

EPS Excl Extra (Annual)$-2.65

CapEx CAGR (5Y)-36.90%

26-Week Price Return-1.88%

Quick Ratio (Annual)0.80x

13-Week Price Return-34.88%

Total Debt / Equity (Annual)1.99x

Current Ratio (Quarterly)1.94x

Enterprise Value$65.81M

Revenue / Share Growth (5Y)11.09%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-22.70%

Revenue / Employee (Annual)$2,500

Inventory Turnover (Annual)0.82x

Pretax Margin (Annual)-13086.50%

Cash / Share (Annual)$0.48

3-Month Return Std Dev58.47%

Gross Margin (5Y Avg)79.00%

Net Income / Employee (TTM)$-424,200

ROE (Last FY)-369.71%

Net Interest Coverage (Annual)-7.67x

EPS Basic Excl Extra (Annual)$-2.65

Receivables Turnover (TTM)6.25x

Total Debt / Equity (Quarterly)6.36x

EPS Incl Extra (TTM)$-3.18

Receivables Turnover (Annual)6.25x

ROI (TTM)-117.21%

P/S Ratio (TTM)399.56x

Pretax Margin (5Y Avg)-7990.97%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.04

Price vs S&P 500 (52W)-39.95%

Year-to-Date Return-24.45%

5-Day Price Return8.44%

EPS Normalized (Annual)$-2.65

ROA (5Y Avg)-93.15%

Net Profit Margin (Annual)-13086.50%

Month-to-Date Return-11.57%

Cash Flow / Share (TTM)$-0.43

EBITD / Share (Annual)$-2.19

Operating Margin (Annual)-11541.50%

LT Debt / Equity (Annual)0.53x

ROI (5Y Avg)-195.19%

LT Debt / Equity (Quarterly)1.66x

EPS Basic Excl Extra (TTM)$-3.18

P/TBV (Quarterly)2.76x

P/B Ratio (Annual)2.84x

Inventory Turnover (TTM)0.35x

Pretax Margin (TTM)-25009.70%

Book Value / Share (Annual)$2.09

Price vs S&P 500 (13W)-37.67%

Beta0.93x

Revenue / Share (TTM)$0.01

ROE (TTM)-322.23%

52-Week Low$3.88

vGradeF

gGradeF

mGradeC

vgmGradeD

CLNN Earnings Surprise History

Q2 25-0.88est. -0.46

Q3 25-0.61est. -0.56

Q4 25-0.78est. -0.42

Q1 26-0.24est. -0.70

Q2 26-0.48est. -0.26

CLNN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.08

4.09

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
CLNNClene Inc. Common Stock	F	F	C	$4.44
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Clene Inc. Common Stock

Clene Inc is a clinical-stage pharmaceutical company developing novel clean-surfaced nanotechnology (CSN) therapeutics for neurodegenerative diseases. The company uses its proprietary electro-crystal-chemistry platform to produce concentrated, stable nanocrystal suspensions. It operates a dietary supplements business with products including CNM-Au8, CNM-ZnA, and CNM-AgZn17.